We provide funding so the brightest minds in pediatric cancer research can find the next big breakthrough.
What We Fund
To call pediatric cancer research “underfunded” is putting it lightly. Among the 12 different types of childhood cancers – yes, there are 12, with dozens of subtypes – the rarest of cancers go for decades without any progress.
Although we’ve made great strides in treating some childhood cancers in the past 50 years, current treatment protocols cause long-term, chronic health problems for survivors like organ damage, fertility issues, and even secondary cancers.
We seek solutions for the underdogs – the rare childhood cancers – so kids living with cancer don’t just survive, but thrive.
Since 2010, we have awarded $1,400,000 in Childhood Cancer Research Grants to nineteen institutions worldwide. Our researchers are searching for more effective treatment options, and for a better understanding of how childhood cancers behave.
Meet Our 2016 Pablove Childhood Cancer Researchers
Gregory J. Aune, M.D., Ph.D.
UT Health Science Center San Antonio
Who is Dr. Aune?
Dr. Gregory John Aune is a Stephanie Edlund Distinguished Professor in Pediatric Cancer Research. He earned his Ph.D. and M.D. from University of Texas Health Science Center. Personal and professional experiences in pediatric cancer fueled his interest in childhood cancer. He is a long-term survivor of Hodgkin’s lymphoma.
What is Dr. Aune currently researching?
Pre-clinical Evaluation of Anthracycline Equivalency
Recent studies have linked cancer therapy with cardiac disease in adulthood. The overall goal of my research is to understand how pediatric cancer treatments damage the heart and develop new strategies to decrease heart disease in long-term cancer survivors of childhood cancer. My long-term career goal is to identify the mechanisms that cause cardiac disease in childhood cancer survivors. – Dr. Aune
View the illustration of Dr. Aune’s research by Rachel Ignotofsky
Ranjit S. Bindra, M.D., Ph.D.
Yale University School of Medicine
Who is Dr. Bindra?
Dr. Ranjit S. Bindra is an Assistant Professor of Therapeutic Radiology at Yale University. He earned his Ph.D. in experimental pathology and M.D. from Yale University School of Medicine. Dr. Bindra completed his residency in radiation oncology at Memorial Sloan-Kettering Cancer Center. He is a recipient of the Marie Curie Award.
What is Dr. Bindra currently researching?
Small Molecule Screening for Novel Rhabdoid Tumor Inhibitors
Atypical Teratoid/Rhabdoid Tumors (ATRTs) are rare, but highly aggressive and resistant brain tumors which affect infants and toddlers. Despite aggressive surgery, multi-agent chemotherapy and intensive radiation therapy regimens, patients often recur at the site where the tumor was initially found. These findings have led researchers to test whether novel drugs can be developed, which can be either used alone or combined with radiation therapy and chemotherapy, in order to prevent these tumors from recurring at the original site. My research will screen to identify these novel agents. – Dr. Bindra
This grant is funded by the Nikhil Kondagari Foundation Fund for Rhabdoid Tumor Research. Learn more about our Named Funds at pablove.org/namedfunds.
Prof. Dr. Franz Blaes
Who is Dr. Blaes?
Dr. Blaes has been a Pablove Childhood Cancer Grant recipient from 2015-2017. He investigates a rare condition called opsoclonus-myoclonus-syndrome (OMS) and neuroblastoma-immune system interactions from his laboratory in Germany. His interest in the disease started during a post-doc in the Neuroscience group, Institute of Molecular Medicine in Oxford under the supervision of Angela Vincent and Bethan Lang (another Pablove researcher!). In 2000, he established an OMS research group at Justus-Liebig-University and was also a co-founder of the German OMS parents group. Today, Dr. Blaes is head of the neurological department at the Gummersbach academic teaching hospital and still runs his research group.
What is Prof. Dr. Franz Blaes currently researching?
Modification of Onconeuronal Antigens in the Neuroblastoma of Paraneoplastic OMS by Free RNA
Opsoclonus-myoclonus syndrome, also known as dancing eye syndrome, is a severe disease of the brain. Children with OMS may have uncontrollable eye movement, muscle jerks, and coordination problems. Half of all children with OMS also have neuroblastoma, a tumor that is one of the most frequent childhood cancers. Some research suggests that when the immune system attacks the neuroblastoma tumor, it mistakenly triggers OMS in children. In our research project with Pablove, we are interested in finding out how the immune attack starts in the neuroblastoma tumor. We are investigating how RNA, a kind of genetic material, might be responsible for the immune response against neuroblastoma and against the brain of OMS children. – Dr. Blaes
This grant is funded by the Opsoclonus Myoclonus Syndrome Research Fund. Learn more about our Named Funds at pablove.org/namedfunds.
Kira Bona, M.D., M.P.H.
Dana-Farber Cancer Institute
Who is Dr. Bona?
Dr. Bona has been a Pablove Childhood Cancer Grant recipient from 2015-2017. She is an instructor in Pediatric Hematology/Oncology at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center in Boston, Massachusetts. Dr. Bona received her M.D. from Yale University School of Medicine, and completed her residency in Pediatrics at Boston’s Children’s Hospital and Boston Medical Center. Dr. Bona’s research is focused on understanding the contribution of poverty to pediatric outcomes. The guiding idea underlying her research is that family poverty, specifically material hardship such as food, housing, and energy insecurity – is prevalent in the childhood cancer population and has an effect on child health outcomes.
What is Dr. Bona currently researching?
Development of a Material Hardship Intervention
While childhood cancer does not discriminate and affects kids from all walk of life, my research fosuses on understanding how poverty affects childhood cancer outcomes. Research has shown poverty is correlated with negative health outcomes, including death, in pediatric primary care and chronic illness. Poverty’s impact on pediatric oncology outcomes is less understood. My research has included studies identifying the prevalence of material hardship in pediatric oncology families as well as the impact of income-poverty on the survival of children with acute lymphoblastic leukemia. I am currently working on an embedded investigation of concrete material hardship in a multicenter clinical trial for children with acute lymphoblastic leukemia. – Dr. Bona
View the illustration of Dr. Bona’s research by Rachel Ignotofsky
Kevin Jones, M.D.
University of Utah
Who is Dr. Jones?
Dr. Kevin Jones is an Investigator and Huntsman Cancer Institute (University of Utah) and an Associate Professor of Orthopaedics and Oncological Sciences and the University of Utah. He earned his M.D. from Johns Hopkins University. As an orthopaedic surgeon by training, he specializes in the care of pediatric patients with sarcoma.
What is Dr. Jones currently researching?
Role of MITF in Clear Cell Sarcomagenesis
Clear cell Sarcoma (CCS) is a rare, but deadly soft-tissue cancer disproportionately affecting children and adolescents. CSS results from one simple—but powerful—genetic change, typically from a stem cell in the deeper soft-tissues of limbs or the body wall. We want to test whether the MITF-M gene is a potential driver of this disease and whether it determines how clear cell sarcomas interact with their environment. – Dr. Jones
Apply for a Grant
What We Fund
The Pablove Foundation invites pediatric cancer researchers to apply for The Foundation’s seed grant program, which provides an award of $50,000 to conduct innovative, cutting edge investigations, with preferences going toward less common childhood cancers.
In addition, projects that focus on Opsoclonus-Myoclonus Syndrome (OMS) will be considered.
The Pablove Foundation is interested in principal investigators who will join us in taking risks, pushing for new solutions, and harnessing the transformative power of science in their research in the following broad areas:
- Mechanisms of Disease
- Preclinical Models
- Biomarkers and Surrogate Markers
- Prognostic Factors
- Innovative Clinical Therapeutic Trials
- Minimal Residual Disease Detection
- Supportive Care and Prevention
- Amelioration of Long-Term Effects of Therapy
By seeking answers and adding to the body of knowledge in pediatric cancer research, The Pablove Foundation will make an impact on the lives of children who are affected by childhood cancer.
Who is Eligible to Apply?
Senior postdoctoral fellows and junior faculty who hold M.D.s or Ph.D.s. In addition, established scientists who are re-directing their research are also eligible to apply for seed funding. Non-US Citizens and international institutions are eligible to apply.
What Can the Funds Be Used For?
$50,000 may be used for direct costs that cover investigators’ salaries, supplies, technical help and travel. In lieu of indirect costs, a maximum of 5% of the grant amount will be provided to sponsoring institutions upon submission of the progress report. The funds cover one year of funding. Grantees who wish to continue gathering preliminary data to prepare for support past the seed stage may apply for an additional year of funding.
The Review Process
The first stage of providing a fair and expert review for grant applications submitted to The Pablove Foundation consists of scientific peer review by a group of highly esteemed scientists who make up our Scientific Advisory Committee.
Applicants must first submit a Letter of Intent (LOI) through the proposalCENTRAL system.(NOTE: You must click “login” to begin the proposal process.) All LOIs are vetted through a competitive peer review process. Based on scores, a limited number of applicants whose LOIs are deemed most meritorious will be invited to submit Full Research Proposals to be considered for the available grants. The peer review panel uses standard guidelines for scoring applicants with an emphasis on innovation, scientific rigor, and relevance to the mission of The Pablove Foundation.
While review critiques will be returned to the proposal PI, final scores will not be provided.
Letters of Intent (LOI)
Investigators who wish to submit a Letter of Intent (LOI) describing a project that fits within The Pablove Foundation Childhood Research Grants project priority areas must complete the proposalCENTRAL LOI instructions and include the following:
A. Applicant Profile, including:
1) Contact Information
2) Institutional Information
3) Educational Background
4) Research Interests
5) Publication History
6) Current and Pending Support
B. Project Summary, including:
1) Lay Summary
2) Scientific Summary including:
a) Specific Aims
b) Rationale and Approach
c) Innovation, Potential and future Patient Benefit
C. Budget Summary for one year
D. Relevant references to support the PI’s hypothesis must be uploaded as a PDF and limited to 1 page
E. NIH Biosketch, uploaded as a PDF
To begin the LOI Process, please create an account or login here. (NOTE: You must click “login” to begin the proposal process.) Once you create an account, you can save and come back to your application at any time. Applications for our 2016 Grant Cycle have officially closed. Letter of Intent (LOI) submissions for our 2017 Grant Cycle will open in October 2016.
Need Help? Get help quickly from proposalCENTRAL Customer Support by e-mail or by phone!
Normal Business Hours: 8:30am – 5:00pm Eastern Time
For questions about the Pablove Grant process, please email firstname.lastname@example.org. No phone calls regarding pending applications, please.
October 15, 2015 – LOI Process Open
November 30, 2015 – Deadline for LOIs (5:00 p.m. Eastern Time)
January 15, 2016 – LOI Applicants Notified of Status
January 15, 2016 – Full Application Process Open to Invited PIs
March 1, 2016 – Full Application Deadline
May 31, 2016 – Grantee Award Notification
September 2016 – Pablove Foundation Award Announcement
July 1, 2016 to June 30, 2017 – Award Dates